Your browser doesn't support javascript.
loading
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Benschop, Robert J; Chow, Chi-Kin; Tian, Yu; Nelson, James; Barmettler, Barbra; Atwell, Shane; Clawson, David; Chai, Qing; Jones, Bryan; Fitchett, Jon; Torgerson, Stacy; Ji, Yan; Bina, Holly; Hu, Ningjie; Ghanem, Mahmoud; Manetta, Joseph; Wroblewski, Victor J; Lu, Jirong; Allan, Barrett W.
Afiliação
  • Benschop RJ; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Chow CK; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Tian Y; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Nelson J; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
  • Barmettler B; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
  • Atwell S; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
  • Clawson D; c Discovery Chemistry Research and Technologies, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Chai Q; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
  • Jones B; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
  • Fitchett J; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
  • Torgerson S; d Department of Drug Disposition Development/Commercialization; Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Bina H; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Hu N; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Manetta J; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Wroblewski VJ; d Department of Drug Disposition Development/Commercialization; Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Lu J; a Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Corporate Center , Indianapolis , IN , USA.
  • Allan BW; b Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company , San Diego , CA , USA.
MAbs ; 11(6): 1175-1190, 2019.
Article em En | MEDLINE | ID: mdl-31181988
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Anticorpos Biespecíficos / Interleucina-17 / Fator Ativador de Células B / Anticorpos de Cadeia Única Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: MAbs Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Anticorpos Biespecíficos / Interleucina-17 / Fator Ativador de Células B / Anticorpos de Cadeia Única Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: MAbs Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos